Navigation Links
PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy
Date:11/15/2007

First and Only Peginterferon Therapy Approved for Retreating Both Hepatitis

C Relapsers and Nonresponders

KENILWORTH, N.J., Nov. 15 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced that the European Commission on October 30 approved 48-week standard-dose PEGINTRON(TM) (peginterferon alfa- 2b, 1.5 mcg/kg once weekly) and REBETOL(R) (ribavirin, 800 - 1,400 mg daily) combination therapy for retreating adult patients with chronic hepatitis C whose prior treatment with interferon alpha (pegylated or non-pegylated) and ribavirin combination therapy or interferon alpha monotherapy did not result in a sustained response. PEGINTRON and REBETOL is the first and only pegylated interferon combination therapy approved in the European Union (EU) for retreating both hepatitis C relapsers and nonresponders.

The European Commission approval of this expanded indication for PEGINTRON and REBETOL results in Marketing Authorization with unified labeling that is valid in the current EU 27 member states as well as in Iceland and Norway.

"This approval is an option for the large number of hepatitis C patients who failed prior therapy because it gives them a second chance at success," said Nadine Piorkowsky, president of the European Liver Patient Association (ELPA). "These patients want to eradicate the virus and now can determine after 12 weeks of retreatment with PEGINTRON combination therapy whether they are likely to go on to achieve a sustained response with a 48-week course of therapy."

The approval is based on results from an ongoing non-comparative clinical study (EPIC3)(1) in which 1,336 patients with moderate to severe fibrosis or cirrhosis who failed pre
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2007 PR Newswire.
All rights reserved

3

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. $52.5 Million Settlement Against Sepracor Inc. Approved
2. FDA Cracks Down on Unapproved Cough Medicines
3. Video: New FDA-Approved Sun Protectant Saves Skin All Year Round
4. Optometry-Backed Vision Care for Kids Act Approved by U.S. House
5. Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis
6. A fresh look at existing therapies: Researchers explore ways to teach approved drugs new tricks
7. Barrs Generic Version of Estrostep(R) Fe Tablets Approved
8. Eligard(R) six-month formulation successfully completes European approval procedure
9. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
10. Medical Services International Inc. Completes Testing for European Union (EU) Application
11. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... Beach, Delaware (PRWEB) May 24, 2013 ... Mushrush has joined the Dayna Feher team at the ... Mushrush made the Delaware resorts her home in 1975. ... has since worked in all aspects of the real ... and for the past 12 years, a licensed sales ...
(Date:5/24/2013)... With Memorial Day Weekend upon us, cookout season has ... tips to help prevent grill fires throughout the spring and ... reports that gas grills led to an average of 7,100 ... grills, meanwhile, caused approximately 1,200 home fires per year during ... sharing the following tips from the NFPA to help protect ...
(Date:5/24/2013)... News) -- New research suggests a link between ... insomnia. Every additional hour someone with insomnia ... in the likelihood of moderate or high risk ... of Pennsylvania. "We were surprised by ... and suicide risk," study author, Linden Oliver, clinical ...
(Date:5/24/2013)... (PRWEB) May 24, 2013 CHI-California ... Appropriators and the California congressional delegation, joined by ... sequestered industry user fees paid to the U.S. ... ensure that future across-the-board cuts will not include ... the FY14 Agriculture, Rural Development and FDA Appropriations ...
(Date:5/24/2013)... -- Drugs commonly used to treat glaucoma may cause ... with vision, according to a new study. The ... to reduce eye pressure, have already been shown to ... the researchers said, suggesting that the new findings could ... should be conservative when prescribing these drugs, the researchers ...
Breaking Medicine News(10 mins):Health News:Tammy Mushrush Joins ResortQuest Real Estate® and the Dayna Feher Team 2Health News:Don’t Get Burned: Five Grilling Tips from Amica Insurance 2Health News:Sleep Duration Linked to Suicidal Thoughts in People With Insomnia 2Health News:California Biomedical Industry Leaders Urge Congress to Take Action on FDA User Fees for FY2014 2Health News:California Biomedical Industry Leaders Urge Congress to Take Action on FDA User Fees for FY2014 3Health News:Common Glaucoma Drug May Cause Droopy Eyelids, Study Finds 2
... /CTL/ -- CareToLive, a not for,profit corporation, received a ... its fight against the FDA on behalf of terminal ... an,appeal in the 6th Circuit Court in Ohio., ... outside of,their grasp," said CareToLive spokesperson, Melody Davis. "Congress ...
... N.J., Nov. 26 Quest Diagnostics,Incorporated (NYSE: ... information and services, announced that it is scheduled ... Conference at the Merrill,Lynch Headquarters in New York ... presentation is scheduled to begin at 10:15 a.m. ...
... are not the best for them, study says , , ... third of prostate cancer patients may receive treatments that ... with urinary, bowel or sexual function, a new study ... give enough information to their doctor or because their ...
... NASDAQ: CRME TSX: COM, VANCOUVER, Nov. 26 /PRNewswire-FirstCall/ ... announced updated guidance for expected,interim results from its Phase ... to complete and disclose the interim,analysis in the fourth ... disclose the interim analysis in March 2008, with the ...
... (p. 30). Senior Writer Suzanne Smalley looks at,GOP presidential ... code, which is at once rigid (in public) and ... adult personality,can be traced back to his childhood and ... family of cops and hoods and to a Catholic ...
... dental care can even start in the womb, experts say ... of Americans is improving as people take better care of ... of the country,s most vulnerable individuals -- children. , Studies ... One federal report found that decay in baby teeth among ...
Cached Medicine News:Health News:CareToLive Reports: The FDA Fiddles While 30,000 Men Burn 2Health News:CareToLive Reports: The FDA Fiddles While 30,000 Men Burn 3Health News:Quest Diagnostics to Speak at the Merrill Lynch Health Services Investor Conference 2Health News:Prostate Cancer Treatments Often Compound Existing Health Problems 2Health News:Prostate Cancer Treatments Often Compound Existing Health Problems 3Health News:Prostate Cancer Treatments Often Compound Existing Health Problems 4Health News:Cardiome Updates Guidance 2Health News:Cardiome Updates Guidance 3Health News:Cardiome Updates Guidance 4Health News:NEWSWEEK: Media Lead Sheet/December 3, 2007 Issue (on newsstands Monday, November 26). 2Health News:NEWSWEEK: Media Lead Sheet/December 3, 2007 Issue (on newsstands Monday, November 26). 3Health News:NEWSWEEK: Media Lead Sheet/December 3, 2007 Issue (on newsstands Monday, November 26). 4Health News:Tooth Decay Is Kids' Stuff 2Health News:Tooth Decay Is Kids' Stuff 3
(Date:5/24/2013)... May 24, 2013 /PRNewswire-iReach/ -- Phoenix Houses of ... abuse services organization, is hosting its tenth annual "Triumph ... on June 6, 2013.  More than 300 people are ... the adolescent residential treatment centers, family therapy, and prevention ... whose accomplishments have positive influences on the health and welfare ...
(Date:5/24/2013)... May 24, 2013  Auxilium Pharmaceuticals, Inc. (Nasdaq: ... participate in the Deutsche Bank Health Care Conference to ... Hotel.  Mr. Adrian Adams , Chief ... overview of the Company and its product pipeline at ... (Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO ) The ...
(Date:5/23/2013)... , May 24, 2013 3SBio Inc. ... "Company"), a leading China -based ... marketing biopharmaceutical products, announced today that, at an ... Company,s shareholders voted in favor of the proposal ... and plan of merger dated February 8, 2013, ...
Breaking Medicine Technology:Phoenix House Honors Allergan Chairman David Pyott And Legendary Sports Agent And Humanitarian, Leigh Steinberg 2Phoenix House Honors Allergan Chairman David Pyott And Legendary Sports Agent And Humanitarian, Leigh Steinberg 3Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 2Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 3Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 43SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 23SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 3
... -- The Six-Month Primary Efficacy Endpoint ... Significantly Increased "ON" Time in,Levodopa-Treated Patients With mid- to Late-Stage ... Endpoints of the Study Analyzed to Date Were met in,Both ... a division of Merck KGaA, Darmstadt, Germany, and its,partner Newron ...
... NEW YORK, Feb. 2 A study led by ... has identified a gene associated with the development of ... With funding provided by the Dystonia Medical Research Foundation ... mutations in the THAP1 gene cause DYT6 dystonia in ...
Cached Medicine Technology:Merck Serono's Safinamide Significantly Improved Motor Function in Patients With Advanced Parkinson's Disease in a Phase III Pivotal Trial 2Merck Serono's Safinamide Significantly Improved Motor Function in Patients With Advanced Parkinson's Disease in a Phase III Pivotal Trial 3Merck Serono's Safinamide Significantly Improved Motor Function in Patients With Advanced Parkinson's Disease in a Phase III Pivotal Trial 4Merck Serono's Safinamide Significantly Improved Motor Function in Patients With Advanced Parkinson's Disease in a Phase III Pivotal Trial 5Merck Serono's Safinamide Significantly Improved Motor Function in Patients With Advanced Parkinson's Disease in a Phase III Pivotal Trial 6Genetic Research Leads to New Discovery in Understanding Rare Neurological Disorder 2
... Since 1991 Intersurgical ... breathing filters, heat and ... oxygen therapy products, hand-held ... range of accessories and ...
... product line has the right product for ... and from intubated patients to patients with ... both anesthesia and critical care applications., ... protection for patients and staff members. This ...
Bacterial/Viral Filters for Anesthesia and Respiratory Applications...
Ballard trach care HMES and filters, universal use, "Y" filter, CO 2 sampling port...
Medicine Products: